(Reuters) – The European Union’s drug regulator said https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-september-2021 on Friday there is a possible link between rare cases of bloods clots in deep veins with Johnson & Johnson’s COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot.
The European Medicines Agency also recommended immune thrombocytopenia (ITP), a bleeding disorder caused by the body mistakenly attacking platelets, be added as an adverse reaction with an unknown frequency to the J&J vaccine product information and to AstraZeneca’s vaccine.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Maju Samuel)
